The Bull Case For Jazz Pharmaceuticals (JAZZ) Could Change Following Worldwide Rights Deal For Epilepsy Candidate

• On August 20, 2025, Jazz Pharmaceuticals and Saniona announced a global license agreement granting Jazz exclusive worldwide rights to develop and commercialize SAN2355, a selective Kv7.2/Kv7.3 activator in preclinical development for epilepsy and other disorders, with Saniona receiving an upfront payment of US$42.5 million and eligibility for further milestones and royalties.
• This agreement gives Jazz access to a differentiated epilepsy candidate designed to overcome limitations of current treatments, further expanding its neuroscience pipeline and long-term development opportunities.
• We'll examine how acquiring worldwide rights to SAN2355 may influence Jazz Pharmaceuticals' pipeline diversification and future growth prospects.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Jazz Pharmaceuticals Investment Narrative Recap

To be a shareholder in Jazz Pharmaceuticals today, you have to believe in the company's ability to replace looming revenue losses from Xyrem’s patent expiry and generic threats, by executing on new product launches and pipeline expansion. While the new SAN2355 deal meaningfully strengthens Jazz’s neuroscience pipeline, it remains in preclinical stages and is unlikely to address near-term revenue or risk from generics entering the market, making its short-term impact immaterial. The leading catalyst remains accelerated approvals of dordaviprone and zanidatamab, while the primary risk is margin pressure from generic oxybate entry and regulatory headwinds.

The FDA’s recent accelerated approval of Modeyso™ (dordaviprone) for diffuse midline glioma is the most relevant recent announcement, as it marks the first in a wave of potential new revenue sources for Jazz. However, as generic competition for Xyrem approaches, this underscores how critical it is for Jazz that the commercial rollout and continued trial success for dordaviprone remain on track.

By contrast, investors should be aware that while pipeline deals add long-term potential, the core sleep franchise faces immediate pressure from...

Read the full narrative on Jazz Pharmaceuticals (it's free!)

Jazz Pharmaceuticals' outlook anticipates $4.9 billion in revenue and $869.9 million in earnings by 2028. Achieving this would require 6.5% annual revenue growth and a $1.27 billion increase in earnings from the current -$404.8 million.

Uncover how Jazz Pharmaceuticals' forecasts yield a $183.47 fair value, a 45% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members offer six fair value estimates for Jazz ranging from US$109.65 to an outlier at over US$29,052,147. With Xyrem patent expiration looming, these broad viewpoints highlight differing expectations for Jazz’s future revenue mix and resilience. Explore several analyses for a richer perspective.

Explore 6 other fair value estimates on Jazz Pharmaceuticals - why the stock might be worth 13% less than the current price!

Build Your Own Jazz Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Jazz Pharmaceuticals research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Jazz Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Jazz Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com